Skip to main content

Key Product Details

Species Reactivity

Validated:

Human

Applications

CyTOF-ready, Flow Cytometry, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 136334

Product Summary for Human FGFR3 Antibody

Immunogen

Pool of NS0-derived recombinant human FGF R3 alpha (IIIb) and Sf21-derived FGF R3 alpha (IIIc)

Specificity

Detects the IIIb and IIIc isoforms of human FGF R3 in direct ELISAs and Western blots.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for Human FGFR3 Antibody

Detection of Mouse FGFR3 by Western Blot

Detection of Mouse FGFR3 by Western Blot

TAB cells modulate melanoma cells to express FGFR-3 and its ligand FGF-2 for tumor stroma-tumor cell cross-talk. a WM3749 co-cultured (72 h) with TAB cells (red bar) show increased FGFR-3 mRNA expression when compared with tumors only (open bar) or co-cultured with NB cells (blue bar). b Lysates obtained from pools of melanomas co-cultured (72–120 h) with NB- or TAB cells were probed in western blot with anti-FGFR-3 antibody (left panel), results expressed as relative intensity after beta-actin normalization (right panel). c Melanoma cells co-cultured with TAB cells (72 h) show increased phospho-FGFR-3 expression (right panel; immunofluorescence assays) when compared with melanoma cells alone (left panel) or melanoma cells co-cultured with NB cells (middle panel), scale bars: 40 μm, images captured by Nikon inverted microscope. d Melanoma cells co-cultured with TAB cells (red bar) show increased FGF-2 mRNA expression when compared with melanoma cells alone (open bar) or melanoma cells co-cultured with NB cells (blue bar). e 451Lu and WM989treated with IGF-1 (25 ng/ml/daily for 5 days; red bar) show increased FGFR-3 expression when compared with untreated controls (blue bar), flow cytometry results expressed as net % expression of control antibody. IGF-1 treated melanoma cells (red bars) show higher expression of FGFR-3 compared with untreated cells (blue bars). Bar represents mean + SD of replicate samples. f NB cells treated with FGF-2 (10 ng/ml/daily for 4 days; red bar) show high IGF-1 mRNA expression relative to untreated NB cells (blue bar). g 451Lu and WM989 co-cultured (72 h) with TAB cells in the presence of an anti-IGF-1 neutralizing antibody (10 μg/ml) show decreased FGFR-3 mRNA expression in tumor cells (blue bar) when compared with controls (red bar). h TAB cells co-cultured (72 h) with 451Lu and WM989 in the presence of an anti-FGF-2 neutralizing antibody (1 μg/ml) show decreased IGF-1 mRNA expression in B cells (blue bar) when compared with controls (red bar).Experiments in a, d and f–h were performed using qPCR. In Figures a, d–h, bars represent mean + SE of duplicate samples and are representative of at least two independent experiments. i Summary of cross-talk between melanoma and B cells: FGF-2 is constitutively expressed by tumor cells, released into the microenvironment to bind FGFR-3 on the B cells, activated B cells express increased levels of pro-inflammatory cytokines. IGF-1 released by TAB cells modulates tumor cells to increase their growth, heterogeneity and therapy resistance Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28928360), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human FGFR3 Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

2.5 µg/106 cells
Sample: K562 human chronic myelogenous leukemia cell line

Western Blot

1 µg/mL
Sample: Recombinant Human FGF R3 (IIIb) Fc Chimera (Catalog # 1264-FR)
Recombinant Human FGF R3 (IIIc) Fc Chimera (Catalog # 766-FR)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 2 reviews rated 4 using MAB766 in the following applications:

Published Applications

Read 4 publications using MAB766 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: FGFR3

Fibroblast Growth Factor Receptor 3 (FGF R3) is a type I transmembrane tyrosine kinase receptor that binds FGF ligands along with heparin or heparin sulfate proteoglycans as co‑factors. A segment of the membrane proximal Ig-like domain can be encoded by two different exons resulting in (IIIb) or (IIIc) isoforms. The IIIb or IIIc isoforms recognize FGF -1, -2, -4, -8b, -8e, -8f, -9, and -17b. FGF R3 plays a role in skeletal, brain, lung, intestine, kidney, and skin development.

Long Name

Fibroblast Growth Factor Receptor 3

Alternate Names

CD333, CEK, FGF R3, JTK4

Entrez Gene IDs

2261 (Human); 14184 (Mouse)

Gene Symbol

FGFR3

Additional FGFR3 Products

Product Documents for Human FGFR3 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human FGFR3 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...